| scholarly article | Q13442814 |
| P356 | DOI | 10.1371/JOURNAL.PONE.0185449 |
| P8608 | Fatcat ID | release_ytfqjypt2fabpmiichafkscq3u |
| P932 | PMC publication ID | 5627906 |
| P698 | PubMed publication ID | 28976989 |
| P50 | author | Carmine Zoccali | Q5043714 |
| P2093 | author name string | Francesca Mallamaci | |
| Giovanni Tripepi | |||
| Claudia Torino | |||
| Rocco Tripepi | |||
| Sebastiano Cutrupi | |||
| Patrizia Pizzini | |||
| P2860 | cites work | Selection bias and information bias in clinical research. | Q53066944 |
| Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients. | Q54128852 | ||
| The effect of joint exposures: examining the presence of interaction | Q58948596 | ||
| Effects of vitamin D3 on selected biochemical parameters of nutritional status, inflammation, and cardiovascular disease in patients undergoing long-term hemodialysis | Q84301417 | ||
| Paricalcitol and endothelial function in chronic kidney disease trial | Q85641588 | ||
| Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial | Q86546599 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis | Q30408489 | ||
| Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. | Q34254721 | ||
| Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy | Q34648670 | ||
| The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function | Q35055194 | ||
| Mechanotransduction of bone cells in vitro: mechanobiology of bone tissue | Q35672414 | ||
| Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. | Q35860672 | ||
| A bench to bedside view of uremic toxins | Q37089544 | ||
| Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk | Q37549351 | ||
| The role of asymmetric and symmetric dimethylarginines in renal disease | Q37858880 | ||
| Do we still need cross-sectional studies in Nephrology? Yes we do! | Q40380558 | ||
| Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine | Q40636368 | ||
| Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations? | Q43110675 | ||
| Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension | Q43731673 | ||
| Effect of asymmetric dimethylarginine on osteoblastic differentiation | Q43795974 | ||
| Impact of hyperthyroidism and its correction on vascular reactivity in humans | Q43826707 | ||
| Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. | Q43850038 | ||
| Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor | Q43922999 | ||
| Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension | Q43936736 | ||
| Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes | Q44037432 | ||
| Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. | Q44039655 | ||
| Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats | Q44053195 | ||
| Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients | Q44238651 | ||
| Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease | Q44555808 | ||
| Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women | Q44582485 | ||
| Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay | Q45171320 | ||
| Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. | Q45980479 | ||
| Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study | Q46522420 | ||
| Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach | Q46535487 | ||
| The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine | Q46867931 | ||
| Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol | Q47107685 | ||
| Association between vitamin D status and asymmetric dimethylarginine (ADMA) concentration in the Korean elderly population. | Q47824711 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin D | Q175621 |
| chronic renal insufficiency | Q736715 | ||
| P304 | page(s) | e0185449 | |
| P577 | publication date | 2017-10-04 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Vitamin D and methylarginines in chronic kidney disease (CKD) | |
| P478 | volume | 12 |
| Q92257110 | Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach | cites work | P2860 |
Search more.